Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways

Immunopharmacology and Immunotoxicology

Volumn 39, Issue 1, 2017, Pages 28-36

  Wang, Ke Si ^a   Li, Junbo ^a   Wang, Zhe ^a   Mi, Chunliu ^a   Ma, Juan ^a   Piao, Lian Xun ^a   Xu, Guang Hua ^a   Li, Xuezheng ^a   Jin, Xuejun ^a  

^a YANBIAN UNIVERSITY   (China)

Author keywords

Artemisinin; Inflammation; I B ; MAPK; Nuclear factor B (NF B)

Indexed keywords

ADAPTOR PROTEIN; ARTEMISININ; CASPASE 8; CYCLIN D1; CYCLOOXYGENASE 2; FLICE INHIBITORY PROTEIN; GELATINASE B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; VASCULOTROPIN; AGFG1 PROTEIN, HUMAN; ARTEMISININ DERIVATIVE; NUCLEOPORIN; RNA BINDING PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTEMISIA ANNUA; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DERMATITIS; DOSE RESPONSE; DRUG MECHANISM; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION; ANIMAL; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; IMMUNOLOGY; INFLAMMATION; SIGNAL TRANSDUCTION;

ANIMALS; ARTEMISININS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MICE; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; RNA-BINDING PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 1; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85006957162     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923973.2016.1267744     Document Type: Article

References (42)

1. Sethi G, Ahn KS, Sandur SK, et al. Indirubin enhances tumor necrosis factor-induced apoptosis through modulation of nuclear factor-kappa B signaling pathway. J Biol Chem 2006;281:23425–23435.
2. Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 2009;462:104–107.
3. DiDonato J, Mercurio F, Rosette C, et al. Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996;16:1295–1304.
4. Tu Y., The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nature Med 2011;17:1217–1220.
5. White NJ., Antimalarial drug resistance. J Clin Invest 2004;113:1084–1092.
6. Lai HC, Singh NP, Sasaki T., Development of artemisinin compounds for cancer treatment. Invest New Drugs 2013;31:230–246.
7. Park KH, Yoon YD, Han SB, et al. Artemisinin inhibits lipopolysaccharide-induced interferon-beta production in RAW 264.7 cells:implications on signal transducer and activator of transcription-1 signaling and nitric oxide production. Int Immunopharmacol 2012;14:580–584.
8. Cao Q, Jiang Y, Shi J, et al. Artemisinin inhibits the proliferation, migration, and inflammatory reaction induced by tumor necrosis factor-α in vascular smooth muscle cells through nuclear factor kappa B pathway. J Surg Res 2015;194:667–678.
9. Wang Z, Hu W, Zhang JL, et al. Dihydroartemisinin induces autophagy and inhibits the growth of iron-loaded human myeloid leukemia K562 cells via ROS toxicity. FEBS Open Bio 2012;2:103–112.
10. Aldieri E, Atragene D, Bergandi L, et al. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-kB activation. FEBS Lett 2003;552:141–144.
11. Berasain C, Castillo J, Perugorria MJ, et al. Inflammation and liver cancer:new molecular links. Ann N Y Acad Sci 2009;1155:206–221.
12. Hou J, Wang D, Zhang R, et al. Experimental therapy of hepatoma with artemisinin and its derivatives:in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 2008;14:5519–5530.
13. Deng XR, Liu ZX, Liu F, et al. Holotransferrin enhances selective anticancer activity of artemisinin against human hepatocellular carcinoma cells. Yi xue Ying De wen ban 2013;33:862–865.
14. Weifeng T, Feng S, Xiangji L, et al. Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 2011;18:158–162.
15. Sanchez-Fidalgo S, da Silva MS, Cardeno A, et al. Abarema cochliacarpos reduces LPS-induced inflammatory response in murine peritoneal macrophages regulating ROS-MAPK signal pathway. J Ethnopharmacol 2013;149:140–147.
16. Jin HR, Jin SZ, Cai XF, et al. Cryptopleurine targets NF-kappaB pathway, leading to inhibition of gene products associated with cell survival, proliferation, invasion, and angiogenesis. PLoS One 2012;7:e40355.
17. Jin X, Jin HR, Jung HS, et al. An atypical E3 ligase zinc finger protein 91 stabilizes and activates NF-kappaB-inducing kinase via Lys63-linked ubiquitination. J Biol Chem 2010;285:30539–30547.
18. Wu X, Song M, Rakariyatham K, et al. Inhibitory effects of 4'-demethylnobiletin, a metabolite of nobiletin, on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mouse ears. J Agric Food Chem 2015;63:10921–10927.
19. Ghosh S, Karin M., Missing pieces in the NF-kappaB puzzle. Cell 2002;109 Suppl:S81–S96.
20. Hsu H, Xiong J, Goeddel DV., The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995;81:495–504.
21. Aggarwal BB., Nuclear factor-kappaB:the enemy within. Cancer Cell 2004;6:203–208.
22. Baeuerle PA, Henkel T., Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141–179.
23. Zhang G, Ghosh S., Toll-like receptor-mediated NF-kappaB activation:a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13–19.
24. Gloire G, Legrand-Poels S, Piette J., NF-kappaB activation by reactive oxygen species:fifteen years later. Biochem Pharmacol 2006;72:1493–1505.
25. Ma J, Liang H, Jin HR, et al. Yangonin blocks tumor necrosis factor-α-induced nuclear factor-κB-dependent transcription by inhibiting the transactivation potential of the RelA/p65 subunit. J Pharmacol Sci 2012;118:447–454.
26. Nakano H, Shindo M, Sakon S, et al. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci USA 1998;95:3537–3542.
27. Meshnick SR., Artemisinin:mechanisms of action, resistance and toxicity. IntJ Parasitol 2002;32:1655–1660.
28. Tambo E, Khater EI, Chen JH, et al. Nobel prize for the artemisinin and ivermectin discoveries:a great boost towards elimination of the global infectious diseases of poverty. Infect Dis Poverty 2015;4:58.
29. Napetschnig J, Wu H., Molecular basis of NF-kappaB signaling. Annu Rev Biophys 2013;42:443–468.
30. Huxford T, Huang DB, Malek S, et al. The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 1998;95:759–770.
31. Jacobs MD, Harrison SC., Structure of an IkappaBalpha/NF-kappaB complex. Cell 1998;95:749–758.
32. Viatour P, Merville MP, Bours V, et al. Phosphorylation of NF-kappaB and IkappaB proteins:implications in cancer and inflammation. Trends Biochem Sci 2005;30:43–52.
33. Aggarwal BB., Signalling pathways of the TNF superfamily:a double-edged sword. Nat Rev Immunol 2003;3:745–756.
34. Hsu H, Huang J, Shu HB, et al. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 1996;4:387–396.
35. Stanger BZ, Leder P, Lee TH, et al. RIP:a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513–523.
36. Chinnaiyan AM, O'Rourke K, Tewari M, et al. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505–512.
37. Hoesel B, Schmid JA. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
38. Karin M, Greten FR., NF-kappaB:linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5:749–759.
39. Hirschowitz E, Hidalgo G, Doherty D., Induction of cyclo-oxygenase-2 in non-small cell lung cancer cells by infection with DeltaE1, DeltaE3 recombinant adenovirus vectors. Gene Therapy 2002;9:81–84.
40. Kipanyula MJ, Seke Etet PF, Vecchio L, et al. Signaling pathways bridging microbial-triggered inflammation and cancer. Cell Signal 2013;25:403–416.
41. Gantke T, Sriskantharajah S, Sadowski M, et al. IκB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012;246:168–182.
42. Kyriakis JM, Avruch J., Mammalian MAPK signal transduction pathways activated by stress and inflammation:a 10-year update. Physiol Rev 2012;92:689–737.